NCT06829082Completed
Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia
Clinical Effectiveness, Adherence, Clinical and Paraclinical Outcomes Associated With Tenofovir Alafenamide/Emtricitabine/Bictegravir (TAF/FTC/BIC) in Patients Diagnosed With Human Immunodeficiency Virus HIV) in Colombia: A Real-Life Study
Source: ClinicalTrials.gov · Last updated 17 Feb 2025
Brief summary (registry, in English)
HIV remains a major global health issue, with 38 million people affected, and significant challenges in diagnosis and treatment due to stigma and socioeconomic factors. In Colombia, the epidemic is concentrated among men who have sex with men, with 165,405 people living with HIV and 14,670 new cases reported in 2023. Barriers to treatment access are exacerbated by social factors and Venezuelan migration. While integrase inhibitors like TAF/FTC/BIC have shown effectiveness, real-world data in Colombia is limited. This study evaluates adherence, effectiveness, and clinical outcomes of TAF/FTC/BIC in 169 patients within the EPS SURA program, contributing context-specific evidence.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 161 (actual)
- First submitted
- 3 Feb 2025
- Start date
- 15 Nov 2024
- Primary completion date
- 17 Jan 2025
- Lead sponsor
- Servicios de Salud IPS Suramericana S.A.S
- Diseases
- HIV
- NCT number
- NCT06829082
What you commit to
- Study type: Observational
- Participants enrolled: 161
- From 15 Nov 2024 to the primary completion date, 17 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a concurrent diagnosis of tuberculosis.
- Patients who started treatment with TAF/FTC/BIC but changed providers or discontinued treatment before completing six months of therapy.
Other illness
- Patients with virologic failure.
Other
- Pregnant patients during the study period.
Who the study is looking for
- Male or female patients aged 18 years or older.
- Individuals with a confirmed HIV diagnosis.
- Individuals enrolled in EPS SURA during the study period.
- Patients receiving treatment with the TAF/FTC/BIC regimen.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Servicios de Salud Ips Suramericana S.A.S. Coordinator of this site? Confirm its status | Medellín | Colombia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.